Introduction
Controlled ovarian stimulation (COS) is a standard procedure in intrauterine insemination (IUI) that has resulted in a significant increase in pregnancy rates with respect to rates in non-stimulated IUI cycles (Nuojua-Huttunen et al., 1999; Dickey et al., 2002; Duran et al., 2002; Houmard et al., 2002; Kaplan et al., 2002) . Nevertheless, multifollicular recruitment during COS can bring about a sudden increase in estradiol (E 2 ) serum levels that is enough to induce an LH surge while follicular growth is still in progress. Moreover, it has been calculated that 24% of IUI cycles suffer undesired premature luteinization (Ragni et al., 2004) and this can result in IUI procedure cancellation. Obviously this represents economic and psychological stress for the patients. Thus, to avoid the risk of unexpected premature follicular luteinization, standard procedure induces ovulation as soon as the leading follicle has reached the 18 mm boundary, independently of the number and developmental status of the other recruited follicles (Frydman et al., 1991; Duran et al., 2002) . This will necessarily change the IUI cycle from multifollicular to monofollicular and, consequently, decrease the chances of gestation, since at least two mature follicles ($ 16 mm) are needed to attain an acceptable pregnancy rate in IUI (Nuojua-Huttunen et al., 1999; Dickey et al., 2002; Duran et al., 2002; Houmard et al., 2002; Kaplan et al., 2002) .
The inclusion of the GnRH antagonist in assisted reproduction techniques allows ovulation to be postponed since the antagonist will suppress gonadotrophin release, block the possibility of premature LH surges, and, consequently, premature luteinization of the follicles (Frydman et al., 1991; Diedrich et al., 1994; European and Middle East Orgalutran Study Group, 2001; Fluker et al., 2001) . Furthermore, this control of untimely LH release has been extensively confirmed and demonstrated to successfully protect follicular development against unexpected luteinization in IVF (Diedrich et al., 1994; European and Middle East Orgalutran Study Group, 2001; Fluker et al., 2001; Ricciarelli et al., 2003; Acevedo-Martin et al., 2004) .
With this in mind, we thought that if pregnancy rates in IUI were related to the number of mature follicles present on the day hCG was indicated (Nuojua-Huttunen et al., 1999; Dickey et al., 2002; Duran et al., 2002; Houmard et al., 2002; Kaplan et al., 2002) , and if the limiting factor for follicular development was premature luteinization, why not control unexpected LH surges during the COS -IUI cycles with an antagonist of the GnRH? This would: (i) maintain steady growth up to . 20 mm in diameter among the recruited follicles; (ii) allow us to time ovulation in a synchronized manner with more than one mature follicle and, hopefully, increase pregnancy rates.
Materials and methods

Study design
This study was a multicentre, prospective, randomized study performed from January to June, 2003, in 82 infertile couples to assess the efficacy of GnRH antagonist in COS combined with homologous IUI.
The GnRH antagonist is already routinely used for IVF in our centres, and the patients were recruited following the guidelines set by the Spanish Committee of Assisted Reproductive Techniques, in accordance with the Helsinki Declaration of 1975 on human research.
Inclusion criteria
The main inclusion criteria in women were age between 18 and 38 years, regular menstrual cycle, primary or secondary infertility lasting for $ 12 months, body mass index between 19 and 25 kg/m 2 , normal prolactin levels, normal thyroid function, normal uterine cavity and bilateral tubal patency assessed by hysterosalpingography and/or laparoscopy.
Women with hormone values outside the reference range by day 3 -4 of their menstrual period (FSH levels . 10 mIU/l) and with polycystic ovarian syndrome were excluded from this study.
Semen analysis was performed at least twice and IUI was carried out if the total motile spermatozoid swim-up count was . 10 £ 10 6 /ml.
Hormonal treatment COS was performed in both groups with recombinant FSH (rFSH, Puregon; Organon Inc., Spain). Patients included in this study underwent an ultrasound scan between the third and fourth day of their menstrual cycle and were subsequently randomized by a computer-generated random listing into two groups. The study was performed in two centres. Patients were randomly assigned by a computer-generated list in the order of their enrolment.
GnRH antagonist group
Forty patients (30 patients from the first centre and 10 from the second centre) were subjected to a COS protocol in which the LH surge was suppressed with the GnRH antagonist ganirelix acetate (Orgalutran; Organon Inc., Spain), as follows. On the third or fourth day of their menstrual period, the patients were examined by ultrasound to ensure ovarian quiescence. A fixed dose of 100 IU/per day of rFSH was then given to induce follicle recruitment for 5 days. At day 6 of ovarian stimulation, an ultrasound was performed to adjust FSH dose, if necessary. When the recruited follicles were $ 16 mm or E 2 levels were . 300 pg/ml, 0.25 mg of ganirelix was subcutaneously injected daily following the manufacturer's guidelines until the day hCG was given. Subsequently, follicular development was controlled by sequential ultrasound scans every 2 days. When adequate ovarian response was observed (follicles =20 mm), 5000 IU/i.m. hCG (hCG-Lepori; Farma-Lepori, Spain) was administered. IUI was cancelled if more than four follicles (.16 -20 mm) were present, in order to reduce the risk of multiple pregnancy. No severe ovarian hyperstimulation syndrome occurred. One cycle was converted to an IVF cycle due to excessive ovarian response (eight follicles $16 mm).
Control group
Forty-two patients (31 from the first centre and 11 from the second centre) were subjected to the same COS protocol previously described except that the GnRH antagonist (Ganirelix) was not used and hCG (5000 IU) was administered once the leading follicle reached the 18 -20 mm boundary, on ultrasound examination. As in the other group, IUI was cancelled if more than four follicles (. 16 -20 mm) were present. One cycle was cancelled in order to avoid a multiple pregnancy since ultrasound had revealed seven follicles $16 mm.
Semen preparation
Semen specimens were obtained by masturbation into a sterile jar after 2 -3 days of abstinence and a few hours before the scheduled insemination. After liquefaction for , 20 -30 min, the specimen was mixed and diluted with 2 ml of Ham's F-10 medium (Gibco, UK) The mixture was centrifuged at 600g for 5-10 min, and the supernatant discarded; 0.3 ml of IVF Universal medium (Medicult, Denmark) was added and the mixture incubated for 30 -45 min at room temperature. After the swim-up, the most active motile sperm were isolated by aspiration and used for insemination.
IUI procedure and luteal phase support A single insemination was performed, 36 -38 h post-hCG, in both groups using a Lee catheter (Vygon, France) inserted through the cervix. A limited insemination volume (0.3 ml) was delivered into the uterine cavity and bed rest was maintained for 10 min after IUI.
The luteal phase was routinely supplemented (in all patients in both groups) with 300 mg/day/vaginally of natural micronized progesterone (Utrogestan; Seid, Spain) starting after the IUI procedure on the same day.
Sixteen days after the insemination, an hCG assay (HCG; BioMerieux, France) was performed. If the assay was positive, transvaginal ultrasonography was scheduled for 2 weeks later. The concurrency of a positive hCG and embryo(s) with a positive heart beat (seen by ultrasound) was defined as a clinical pregnancyotherwise the positive hCG test was considered to be a biochemical pregnancy. Progesterone was maintained until the 12th week of pregnancy if a clinical pregnancy was evident.
Hormonal determination FSH, LH, E 2 and hCG serum levels were determined with a commercial enzyme immunoassay kit (Vidas; Biomérieux, Spain). Blood samples were collected on the third or fourth day of the cycle (E 2 , LH and FSH) and before given hCG (E 2 ).
Statistical analysis
Data were expressed as the mean^SD. Continuous variables were compared with Student's t-test. The x 2 -test and Fisher test were used to compare clinical outcome between the two groups. The analysis was carried out using the statistical package for social sciences (SPSS Inc., USA). P , 0.05 was considered significant.
Results
To determine the impact that inclusion of GnRH antagonist in COS -IUI cycles may have on pregnancy rates, 82 patients were randomly divided as described in Materials and methods.
As seen in Table I , no significant differences in basal serum levels (third and fourth days of their menstrual cycle) for FSH (5.5^2.1 versus 6.1^1.7), LH (4.7^4.2 versus 6.1^4.8) or E 2 (38.2^15.4 versus 38.3^12.7) were noted between the GnRH antagonist-treated group and the control group. No significant differences in the total amount of rFSH (707^240 versus 657^194 total IU) and E 2 serum levels (428^154 pg/ml versus 598^167 pg/ml) were seen between the GnRH antagonist and the control groups (Table II) .
Nevertheless, the number of mature follicles ($ 16 mm in diameter) determined by ultrasound before beginning hCG was significantly higher in patients receiving GnRH antagonist than in the control group (2.4^1.4 versus 1.7^1.2, P , 0.05). As expected, cycle length was extended to almost 1 day more (7.6^1.9 versus 6.6^1.8 days) in the GnRH antagonist group than in the control group, although this difference was not statistically significant.
Pregnancy rates were significantly increased in the group of patients receiving the GnRH antagonist (38%) compared to the control group (14%). To date, except for one biochemical pregnancy in the control group, all the other pregnancies are ongoing. Furthermore, 93% of the pregnancies in the GnRH antagonist group (14/15) and 100% of the pregnancies in the control group (6/6) were single gestations. The only nonsingle pregnancy (triplets) occurred in the antagonist group.
Discussion
The purpose of this preliminary study was to determine if the inclusion of a GnRH antagonist (ganirelix acetate) in COS -IUI protocols could significantly increase the number of mature follicles and, by extension, improve pregnancy rates, since these two parameters are known to be positively correlated (Nuojua-Huttunen et al, 1999; Dickey et al., 2002; Duran et al., 2002; Houmard et al., 2002; Kaplan et al., 2002) .
The rationale for this hypothesis was based on the capacity of the GnRH antagonist to rapidly inhibit LH release by the gonadotrophs and thereby control and avoid premature luteinization in IVF (Frydman et al., 1991; Diedrich et al., 1994; Reissmann et al., 1995; Olivennes et al., 2002) . We thought that the same mechanism could be used in COS -IUI advantageously to avoid premature luteinization of the leading follicle(s) and to expand follicular development so that ovulation could be induced once follicle size was between 19 and 20 mm. Furthermore, since COS generally develops a cohort of follicles, avoiding premature luteinization with ganirelix acetate would increase the number of ovulatory follicles available for the IUI procedure and, hopefully, increase pregnancy rates (Nuojua-Huttunen et al, 1999; Dickey et al., 2002; Duran et al., 2002; Houmard et al., 2002; Kaplan et al., 2002) .
Our results support this hypothesis since the inclusion of the GnRH antagonist (1.8^0.7 ampoules) in the COS -IUI protocol significantly (P , 0.05) increased the number of mature follicles ($ 16 mm) in the GnRH antagonist group with respect to the control group (2.4^1.4 versus 1.7^1.2 respectively). The total amount of FSH used by patients receiving GnRH antagonist (707^240 total IU) was slightly greater than in the controls (657^194 total units), but this difference was not significant (Table II) .
Nevertheless, we were concerned by the increased cost of including the GnRH antagonist in the IUI protocols. We calculated that including this treatment would increase the cost of each cycle by a minimum of e100 and a maximum of e150. In return by using a GnRH antagonist that will significantly reduce the risk of cycle cancellation and the associated emotional stress to the patients.
We were aware of the risk that increasing the number of mature follicles could also increase multiple pregnancy rates (Dickey et al., 2001; Khalil et al., 2001; Tur et al., 2001) , and, in fact, the only multiple gestation in this study was in the group treated with GnRH antagonist (Table III) . For this reason, IUI was cancelled whenever a patient had more than four 16 -20 mm follicles, regardless of how many follicles were , 15 mm (Claman, 2004; Osuna et al., 2004) . Several publications have indicated that the risk of multiple pregnancies rises with the number of 15 mm follicles (Tur et al., 2001; Dickey et al., 2001; Khalil et al., 2001; Ghosh et al., 2003) and some of the follicles we classified as 15 mm could actually have measured 16 mm (given the difficulties of distinguishing between a 16 or 15 mm follicle by ultrasound). However, our clinic's historical average for multiple gestations using the criterion of ignoring the number of , 15 mm follicles when deciding IUI is 20% (only twins, no triplets), so we followed the same rationale in this study and only one couple in the GnRH antagonist group had a multiple pregnancy.
As also described previously in IVF /GnRH antagonist cycles (Diedrich et al., 1994; European and Middle East Orgalutran Study Group, 2001; Fluker et al., 2001; Ricciarelli et al., 2003; Acevedo-Martin et al., 2004) , E 2 serum levels decreased in the GnRH antagonist -IUI group in respect to the control group (428^154 versus 598^167 respectively), although not significantly. This decrease did not affect oocyte differentiation (Hernández, 2000; Tur et al., 2001; Ricciarelli et al., 2003; Acevedo-Martin et al., 2004) since pregnancy rates were significantly increased in patients receiving the GnRH antagonist with respect to the controls (38 versus 14%). Furthermore, at the time of writing, all the pregnancies are ongoing in the GnRH antagonist group and there have been no miscarriages (Table III) . However, it must be remembered that the increases in the pregnancy rate are probably not related to the antagonist itself but to the fact that the use of an antagonist gives the clinician more time to produce more ovulatory follicles that can give rise to a pregnancy.
Although Kolibianakis et al. (2003) report that patients receiving the GnRH antagonist during IVF cycles seem to present a dysfunctional endometrium, Ragni et al. (2001) have demonstrated that the luteal phase profile (progesterone concentration) in COS -IUI/GnRH antagonist cycles seems to be unaffected in IUI cycles treated with recombinant FSH in combination with GnRH antagonist. Nevertheless, to avoid a hypothetical effect of the antagonist on the function of the corpus luteum, we routinely supplemented the luteal phase with natural micronized progesterone in all the IUI procedures.
In conclusion, the addition of the GnRH antagonist to COS -IUI cycles significantly increased pregnancy rates in our patients. Since this increase seems to be related to the number of follicles recruited, clinicians should balance this benefit against the risk of multiple gestation in IUI.
Finally, because only a relatively small number of patients has been analysed, the results of this study are only preliminary. However, in our opinion some immediate emotional and clinical benefits (lower cancellation rates, avoidance of premature luteinization) can be obtained using the GnRH antagonist in the COS -IUI cycles.
